Back to dashboard
CommercialCoverageLow impact

08.02.14a, Casgevy™ (exagamglogene autotemcel)

Independence Blue Cross·Hematology, Oncology·Pharmacy
Effective date
Jul 1, 2025
We identified it
Jun 19, 2026
Days to comply
—

Summary

IBX Commercial updated their policy for Casgevy™ (exagamglogene autotemcel), a gene therapy drug, with changes to coverage position, medical necessity criteria, and general guidelines. This affects pharmacy benefit coverage and reimbursement for this specialized treatment.

Action Required

Action needed
By July 1, 2025: Billing team should review the full policy details at the IBX website to understand new coverage criteria and medical necessity requirements for Casgevy™ prescriptions. Update prior authorization workflows if this gene therapy is prescribed at your practice.

Related policy hubs